Azenta, Inc. - Common Stock AZTA 深 滬
等待開盤 10-03 09:30:00 美东时间
31.49
-0.090
-0.28%
華盛通- 最 高31.81
- 今 開31.67
- 成交量 59.84万股
- 最 低 30.67
- 昨 收 31.58
- 總市值 14.43亿
- 52周最高 55.635
- 市盈率 靜 --
- 換手率 1.31%
- 52周最低 23.91
- 委 比 38.95%
- 總股本 4583.97万
- 歷史最高 124.69
- 量 比 0.84
- 振 幅 3.61%
- 歷史最低 3.92
- 每 手 1
- 風險率 6.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Raymond James Upgrades Azenta to Outperform, Announces $35 Price Target
Raymond James analyst Andrew Cooper upgrades Azenta (NASDAQ:AZTA) from Market Perform to Outperform and announces $35 price target.
08-06 19:29
Azenta Q3 Adj. EPS $0.19 Beats $0.13 Estimate, Sales $144.000M Miss $149.227M Estimate
Azenta (NASDAQ:AZTA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.13 by 43.94 percent. This is a 18.75 percent increase over earnings of $0.16 per share from the same
08-05 18:32
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Azenta Joins Frenova And Nephronomics To Power MyReason Genomics Program Aiming To Transform Precision CKM Disease Care
Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing
08-01 04:44
Evercore ISI Group Maintains In-Line on Azenta, Raises Price Target to $35
Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and raises the price target from $29 to $35.
07-08 20:47
Azenta Life Sciences Partners With Form Bio To Advance AAV Gene Therapy Development
Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.
05-14 04:15
美股大行评级 | 潜在涨幅105.34%！Amylyx Pharmaceuticals获Leerink Partners升目标价至10美元，上调至"跑赢大市"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
05-08 08:45
Needham Maintains Buy on Azenta, Lowers Price Target to $40
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and lowers the price target from $59 to $40.
05-08 02:46
Azenta Q2 Adj. EPS $0.05 Misses $0.07 Estimate, Sales $143.00M Beat $140.91M Estimate
Azenta (NASDAQ:AZTA) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.07 by 28.57 percent. This is unchanged from the same period last year. The company reported quarterly
05-07 18:34
Earnings Scheduled For May 7, 2025
Companies Reporting Before The Bell • Wallbox (NYSE:WBX) is estimated to report...
05-07 16:33
